A controversial hepatitis B vaccine trial in Guinea‑Bissau, planned to enroll 14,000 newborns, is reportedly proceeding according to U.S. officials, despite ethical concerns and reports of its cancellation. The five-year trial, funded by a $1.6 million CDC grant, would randomize infants to receive the vaccine at birth or not, in order to study short-term health effects. Supporters say the study could fill critical evidence gaps on optimal vaccine timing and broader health effects. Critics, however, argue that withholding a proven, life-saving vaccine from infants in a high-risk setting is unethical and have drawn comparisons to the Tuskegee syphilis study. Read more.